Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286028 | 1.00 | HTR4 (0.38) | HTR4CASP6HTTCYP1A2HPGD | |
| SCHEMBL6287877 | 0.81 | HTR4 (0.41) | HTR4KMT2ADAOMCL1 | |
| SCHEMBL20037330 | 0.74 | KMT2A (0.46) | HTTCYP1A2KMT2AMEN1DAO | |
| SCHEMBL4874928 | 0.73 | MCL1 (0.42) | HTTHPGDKMT2AMEN1DAO | |
| SCHEMBL8621736 | 0.72 | SIRT2 (0.43) | HPGDKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL28832049 | 0.69 | KDM4E (0.59) | HTTKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21359462 | 0.69 | OXER1 (0.46) | MCL1ALDH1A1 | |
| SCHEMBL18180382 | 0.68 | KMT2A (0.45) | HTTKMT2ALMNA | |
| SCHEMBL27829684 | 0.68 | KMT2A (0.50) | HTR4HTTKMT2AMEN1LMNA | |
| SCHEMBL8621659 | 0.68 | SIRT2 (0.43) | CYP1A2HPGDKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | disclosed |
| US-6870056-B1 | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6867217-B1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | HTR4 898/4885CASP6 221/4885HTT 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.